摘要
目的 探讨噻托溴铵粉吸入剂对稳定期中重度COPD患者的治疗效果。方法选取我院2010年2月至2012年3月收治的90例稳定期中重度COPD患者90例，随机分为实验组和对照组各45例。两组患者均接受常规治疗，实验组在常规治疗的基础上采用噻托溴铵粉吸入剂。记录两组患者吸人药物前、吸入药物6周和12周的肺功能指标，包括1秒用力呼气量（FEV1）、用力肺活量（FVC）、深吸气量（IC），并记录两组患者的6分钟步行距离（6MWD）和不良反应发生率。结果治疗后6周和12周，实验组FEV1、FVC、IC、6MWD等指标均优于对照组，差异有显著性（P〈0．05）。对照组不良反应发生率为4．4％，实验组为8．9％，差异有统计学意义（P〈0．05）。结论噻托溴铵粉吸入剂对稳定期中莺度COPD患者疗效显著，安全性高，值得临床推广使用。
Objective To explore the effect of tiotropium bromide powder inhalation in treatment of stable moderate to severe chronic obstructive pulmonary disease （COPD）. Methods 90 cases of stable moderate to severe COPD admitted into our hospital from February 2010 to March 2012 were selected as objects. They were randomly divided into control group and experiment group, 45 eases for each group. Routine nursing was given to two groups and tiotropium bromide powder inhalation was given to the experiment group. The pulmonary function indieatrix before taking medicine, 6 and 12 weeks after taking medicine of them was recorded, including FEV 1, FVC, IC, 6MWD and adverse effects rate. Results After 6 and 12 weeks treatment, the FEV1, FVC, IC and 6MWD in the experiment group were superior than those of control group, the difference was statistically significant （P 〈 0.05）. The adverse effects rate was 8.9% in the control group and 4.4% in experiment group, the difference was statistically significant （P 〈 0.05）. Conclusions We think that tiotropium bromide powder inhalation has great effect on stable moderate to severe COPD. It is safe and worth to he widely promoted in clinic.
出处
《国际医药卫生导报》
2013年第8期1094-1096,共3页
International Medicine and Health Guidance News
关键词
噻托溴铵粉吸入剂
稳定期中重度COPD
治疗效果
Tiotropium bromide powder inhalation
Stable moderate to severe chronic obstructive pulmonary disease
Treatment effect
